MedTrace Logo

Comparison of Quantitative Metamorphopsia- Measurements in Patients With mCNV

NCT04112524 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2021-12-09

No results posted yet for this study

Summary

The myopic CNV (mCNV) is a blood vessel neoplasm starting from the choroid, based on pathological myopia (severe myopia).

Choroidal neovascularization secondary to pathological myopia is the most common cause of severe visual impairment in myopic patients younger than 50 years old. Because untreated small fibrovascular membranes cause rapid damage to the photoreceptors, timely treatment is required in view of poor spontaneous prognosis1.

Metamorphopsia is the first functional impairment which occurs in mCNV - visual acuity loss and scotoma follow later.

There is a need for better and quicker quantifying of the metamorphopsia in mCNV patients.

The aim of this study is to detect metamorphopsia and verify correlations of different indexes with disease activity or not, measured in Optical Cohorence Tomography (OCT), best corrected visual acuity (BCVA), Vision related quality of life questionnaire (NEI-VFY-25) and quantify severity of metamophopsia.

Conditions

  • Metamorphopsia

Interventions

DEVICE

App

* Alleye® Test Alleye® Test is a mobile medical software application indicated for the detection and characterization of metamorphopsia. For the mean Alleye score (±standard deviation (SD) deviations of dots from an ideal line are calculated for each eye. * AMD-A Metamorphopsia Detector® Is based on the Amsler grid. The software uses the concept of a negative image: a distorted image can be straightened by moving the mouse. Degree and dimension of distorted lines or scotoma are transformed into indices.

Sponsors & Collaborators

  • PD Dr. med. Katja Hatz

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-08
Primary Completion
2021-02-02
Completion
2021-02-02

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04112524 on ClinicalTrials.gov